The pharmacology of recombinant hirudin, a new anticoagulant

A new anticoagulant, recombinant hirudin, was given to healthy volunteers (5 per test dose) in single .intravenous doses of 0,01, 0,02, 0,04, 0,07 and 0,1 mg/kg to study its anticoagulant effects, how it was tolerated and its pharmacokinetics. Hirudin proved to be a potent anticoagulant with important effects on thrombin (increase in thrombin time and partial thromboplastin time). The maximum pharmacodynamic effect was achieved with the 0,07 mg/kg dose, and upwards. All doses of the compound were tolerated without sideeffects. The mean elimination half-life is about 1 hour. Mean total clearance and volume of distribution are approximately 190 ml/min and 14 I, respectively. Hirudin obeys first-order pharmacokinetics

The efficacy of two bupivacaine hydrochloride injection products

No Abstract

Acquisition and Processing of Cerebral Blood Flow Data with a M;ultichannel Analyser and Microcomputer

The method of the determination of cerebral blood flow in dogs with radio-isotopes to evaluate ethrane as a new anaesthetic agent is described, as well as the use of a multichannel analyser and the programmes developed for the analysis of data in a conversational mode. Preliminary results of the use of the computer programme are presented

The use of renal enzymes as early indication of renal toxicity after multiple dose administration of aspirin

Ten volunteers participated in a study comparing the effects on renal enzymes of multiple oral doses of aspirin relative to no treatment. The total urinary output was collected daily for 21 days from all subjects. The first 7 days were treatment-free. During the second 7-day period the subjects received aspirin 1 500 mg 3 times daily. This was followed by another treatment-free period of 7 days. The activity of the enzymes alanine aminopeptidase and N-acetyl-B-glucosaminidase were determined in each daily urine specimen. Statistical analysis revealed that aspirin significantly increased the output of both enzymes